The new Memorial Sloan Kettering Cancer Center’s recommendations for prostate cancer screening provide a model for prostate cancer screening that maximizes the benefits, in terms of reduction in prostate cancer-specific mortality, and minimizes harms to men from overdiagnosis and overtreatment.
Andrew J. Vickers, PhD, Attending Research Methodologist, is a co-author on this publication, in press. Dr. Vickers’ research interests focus on models for risk prediction in medicine. One of his findings is that a single measure of prostate specific antigen (PSA) taken in middle age can predict aggressive prostate cancer up to 30 years following. He has also developed a statistical model to predict the result of prostate biopsy based on a panel of markers, and commercially available as the 4kScore.
Here, Dr. Vickers speaks to UroToday about the rationale, deliberations, and conclusions of the authors of the new MSK recommendations to guide prostate cancer screening.